Home Market News The Bumpy Road Ahead: Regulus Therapeutics Falls Short on Q4 2023 EPS

The Bumpy Road Ahead: Regulus Therapeutics Falls Short on Q4 2023 EPS

0
The Bumpy Road Ahead: Regulus Therapeutics Falls Short on Q4 2023 EPS
RGLS stock - RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023

Source: iQoncept / Shutterstock

Regulus Therapeutics (NASDAQ:RGLS) has just unveiled its performance for the final quarter of 2023.

  • Regulus Therapeutics posted a disappointing earnings per share of -40 cents, falling short of the forecasted EPS of -39 cents by analysts.
  • The company did not generate any revenue during the quarter.

InvestorPlace Earnings, powered by TradeSmith data, provides automated coverage of quarterly earnings. The feature highlights critical data like earnings per share, revenue figures, and comparisons against analyst predictions. These updates are crafted with precision, ensuring rapid access to important financial insights. For feedback or corrections, reach out to us at [email protected].


Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/rgls-stock-earnings-regulus-therapeutics-for-q4-of-2023/.

©2024 InvestorPlace Media, LLC